Stocks/NCNA

NCNA

NuCana plc
Healthcare·Biotechnology
--
$0M market cap
Revenue
$0.0M
Free Cash Flow
$-0.9M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatmen

2-Year Price History

$2.02-99.7%
$200$400$600$800$1.0k$1.2k$1.4kvolJun 24Oct 24Jan 25May 25Sep 25Jan 26May 26

Quarterly Financials & Projections

Quarterly Waterfall (GBP M)
PeriodRevEBITDAOpInNIOCFFCFCapExCashDebtSharesROICIntCovEV/EBITDA
Act2026-Q10.0-6.4-6.4-5.2-3.10.0-3.121.50.73.7-360.6%----
Act2025-Q40.0-2.8-4.7-2.5-0.9-0.9-0.024.20.73.7-210.6%----

Valuation & Metrics

Market Stats

Price--
Market Cap$0M
Enterprise Value$-21M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield0.0%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD

TTM Financial Snapshot

Revenue$0.0M
Net Income$-7.7M
Free Cash Flow$-0.9M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-285.6%
WC Change % Rev0.0%
Interest Coverage--

Forward Outlook & Risk

Short Interest

Short % of Float--
Short Shares0.2M
Days to Cover7.2
Change (vs Prior)+0.0%
Need at least 2 settlement dates for chart

Employees

Headcount20
Revenue / Employee$0
Gross Profit / Employee$-4,581

Institutional Ownership

Headline & net flow

NEUTRAL
Net flow · —still filing
No float data — flow unavailable.

Ownership composition

Active
0.4%(+0.4% YoY)
5 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
0.0%(+0.0% YoY)
0 filers
Vanguard, iShares, SPDR
Market makers
0.3%(+0.3% YoY)
2 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
0%25%50%75%100%2025-062025-092025-122026-03
ActiveRetail fundsPassiveMarket makersRetail direct

Top holders

Fund$ valueCost basisΔ QoQΔ YoYα lifeFund AUM
Glass Jacobson Investment Advisors llc$21K$4.64+$0+$21K+0.0%$288M
CITADEL ADVISORS LLC$20K$1.40+$19K+$20K-0.4%$138.22B
Virtu Financial LLCMM$19K$1.40+$19K+$19K-2.0%$2.41B
JANE STREET GROUP, LLCMM$15K$4.64−$1K+$15K-0.1%$92.10B
RHUMBLINE ADVISERS$5K$3.70−$2K+$5K+0.4%$116.90B
Caitong International Asset Management Co., Ltd$0$1.40+$0+$0+1.3%$540M
MORGAN STANLEY$0$3.62−$0+$0-0.3%$1.65T
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.

Trading behavior

Smart-money alpha (lifetime, %/qtr)BEARISH
Holders
-0.12%
avg per quarter
Holders (ex-self)
-0.11%
excl. this stock
Buyers (this Q)
-0.40%
3 buyers · $0.00B in
Sellers (this Q)
+0.42%
3 sellers · $0.00B out
alpha coverage: 100% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-4.9%
how holders react when this stock falls
On quiet Qs
-4.4%
−10% to +10% baseline
On rallies (+10%+)
-20.6%
how they react when this stock rises
Holders' portfolio flow this Q
+1.4%
inflows — adds are organic
Sellers' portfolio flow this Q
+7.1%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-9.2%
Holder mid (any stock)
-4.4%
Holder rally (any stock)
-20.6%

Biggest decreases this quarter

Carlyle Group L.P.exited−$480KFNY Investment Advisers, LLCexited−$36KUBS Group AGexited−$13KRHUMBLINE ADVISERS−$2Kα+0.4CITIGROUP INCexited−$1KJANE STREET GROUP, LLC−$1Kα-0.1MORGAN STANLEY−$0α-0.3

New buyers this quarter

CITADEL ADVISORS LLC+$0.00Bα-0.4Virtu Financial LLC+$0.00Bα-2.0Caitong International Asset Management Co., Ltd+$0.00Bα+1.3

Top-5 holders · 100.0%

Glass Jacobson Investment Advisors llc--
CITADEL ADVISORS LLC--
Virtu Financial LLC--
JANE STREET GROUP, LLC--
RHUMBLINE ADVISERS--

Top Holders Over Time

5-year share-count history (top 10 holders by peak, incl. exited) + price

042K84K126K167K$1.40$3.92$6.44$8.96$112025-062025-092025-122026-03
hover the chart for per-quarter detailprice (right axis)
Carlyle Group L.P.—Glass Jacobson Investment Advisors llc15KUBS Group AG—FNY Investment Advisers, LLC—CITADEL ADVISORS LLC14KRHUMBLINE ADVISERS4KGlobal Retirement Partners, LLC—CITIGROUP INC—MORGAN STANLEY2AllSquare Wealth Management LLC—

Analyst Coverage

Analyst Coverage
Analyst Ratings
7
1
Buy: 7Hold: 1Consensus: Buy

Corporate

Order Flow (FINRA, ~3w lag)

47.4%retail+11.3pp
4.8%dark-5.8pp
week of 2026-04-13
0%20%40%60%25-0825-0925-1125-1226-0126-0326-04retail (non-ATS)dark (ATS)
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.

Filing Risk Analysis

Filing Risk Scores

NuCana PLC: A Dilution Death Spiral Masked by Phosphoramidate Science

Overall Risk
9/10
Fraud
4/10
Dilution
10/10
Insolvency
8/10
Earnings Overstated
2/10
Hidden Liabilities
6/10
Legal
3/10
Audit Warnings
9/10
Hidden Upside
2/10
Contextually Acceptable
2/10